Pancreatic cancer: Current standards, working towards a new therapeutic approach

Expert Review of Anticancer Therapy

Volumn 14, Issue 5, 2014, Pages 495-497

  Olowokure, Olugbenga ^a   Qi, Xiaoyang ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; combination treatment; metastases; monotherapy; new approach; pancreatic cancer therapy; resistance; SapC DOPS nanovesicles; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CERAMIDE; CONTRAST MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GADOLINIUM; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLSERINE; SAPOSIN C DIOLEOYLPHOSPHATIDYLSERINE; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REVIEW; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; PANCREATIC NEOPLASMS;

HUMANS; PANCREATIC NEOPLASMS;

EID: 84898989414     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.895937     Document Type: Review

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30
2. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6):1227-34
3. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53
4. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6):2403-13
5. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60(11):2926-35
6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15):1960-6
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
8. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
9. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
10. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28(22):3617-22
11. Alberts SR, Schroeder M, Erlichman C, et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 2004;22(24): 4944-50
12. Chu Z, Abu-Baker S, Palascak MB, et al. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One 2013;8:e75507
13. Qi X, Chu Z. Fusogenic domain and lysines in saposin C. Arch Biochem Biophys 2004;424(2):210-18
14. Qi X, Leonova T, Grabowski GA. Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J Biol Chem 1994; 269(24):16746-53
15. Qi X, Qin W, Sun Y, et al. Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions. J Biol Chem 1996; 271(12):6874-80
16. Wang Y, Grabowski GA, Qi X. Phospholipid vesicle fusion induced by saposin C. Arch Biochem Biophys 2003; 415(1):43-53
17. Abu-Baker S, Chu Z, Stevens A, et al. Cytotoxicity and selectivity in skin cancer by SapC-DOPS nanovesicles. J Cancer Ther 2013;3:321-6
18. Qi X, Chu Z, Mahller YY, et al. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res 2009;15(18): 5840-51
19. Wojton J, Chu Z, Mathsyaraja H, et al. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther 2013;21(8):1517-25
20. Unruh D, Turner K, Srinivasan R, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer 2014;134(1): 9-20
21. Kaimal V, Chu Z, Mahller YY, et al. Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol 2011; 13(5):886-97